Fas ligand and immune evasion

Nature Medicine

Volumn 2, Issue 12, 1996, Pages 1306-1307

  Nagata, Shigekazu ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; TUMOR NECROSIS FACTOR RECEPTOR;

APOPTOSIS; CARCINOGENESIS; CELL DEATH; CYTOTOXIC T LYMPHOCYTE; HUMAN; IMMUNE RESPONSE; NATURAL KILLER CELL; PRIORITY JOURNAL; SHORT SURVEY; TUMOR CELL;

ANIMALS; ANTIGENS, CD95; FAS LIGAND PROTEIN; HUMANS; KILLER CELLS, NATURAL; LIGANDS; MEMBRANE GLYCOPROTEINS; NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0029840585     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm1296-1306     Document Type: Short Survey

References (10)

1. Strand, S. et al. Lymphocyte apoptosis induced by CD95(APO-1/Fas) ligand expressing tumor cells-A mechanism of immune evasion? Nature Med. 2, 1361-1366 (1996).
2. Hahne, M. et al. Melanoma cell expression of Fas(Apo-1/CD95) ligand: Implications for tumor immune escape. Science 274, 1363-1366 (1996).
3. O'Connell, J., O'Sullivan, G.C., Collins, J.K. & Shanahan, F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J. Exp. Med. 184, 1075-1082 (1996).
4. Nagata, S. & Golstein, P. The Fas death factor. Science 267, 1449-1456 (1995).
5. Alnemri, E. et al. Human ICE/CED-3 protease nomenclature. Cell 87, 171 (1996).
6. Nagata, S. & Suda, T. Fas and Fas ligand: lpr and gld mutations. Immunol. Today 16, 39-43 (1995).
7. Bellgrau, D. et al. A role for CD95 ligand in preventing graft rejection. Nature 377, 630-632 (1995).
8. Griffith, T., Brunner, T., Fletcher, S., Green, D. & Ferguson, T. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 270, 1189-1192 (1995).
9. Lau, H., Yu, M., Fontana, A. & Stoeckert, C., Jr. Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice. Science 273, 109-112 (1996).
10. Tanaka, M. et al. Fas ligand in human serum. Nature Med. 2, 317-322 (1996).